抗体偶联药物在卵巢癌中的研究进展

Research progress in antibody-drug conjugates in ovarian cancer

抗体偶联药物是一种由单克隆抗体、连接子和小分子细胞毒药物3部分共价偶联而成的新型抗肿瘤药物。抗体偶联药物因兼具细胞毒药物的强大杀伤肿瘤细胞作用及抗体的精准靶向作用,且治疗相关不良反应较少,近年来成为临床研究的热点。抗体偶联药物药物除在乳腺癌、肺癌、胃癌、血液系统肿瘤等领域表现出优异的临床疗效外,对女性卵巢癌的临床研究也逐渐增多。该文重点对近年来抗体偶联药物在卵巢癌中不同作用靶点的研究进展展开综述,以期为卵巢癌患者的临床治疗提供新的参考依据。

Antibody-drug conjugates is an innovative antineoplastic drug consisting of a three-part covalent coupling of a monoclonal antibody,a linker and a small-molecule cytotoxic drug.Antibody-drug conjugates have become a hot topic of clinical research in recent years because they combine the powerful tumor-killing effect of cytotoxic drugs with the precise targeting effect of antibodies,and have low treatment-related adverse effects.Besides showing excellent clinical efficacy in breast cancer,lung cancer,gastric cancer and hematologic tumors,antibody-drug conjugates are gradually increasing clinical studies in women ovarian cancer.This article systematically reviewed the recent progress in the different targets of antibody-drug conjugates in ovarian cancer,so as to provide new reference for the clinical treatment of ovarian cancer patients.